

%STN;HighlightOn= ***;HighlightOff=*** ;

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1648rx1

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

```
NEWS 1 Web Page for STN Seminar Schedule - N America
NEWS 2 STN pricing information for 2008 now available
NEWS 3 CAS patent coverage enhanced to include exemplified
      prophetic substances
NEWS 4 USPATENT, USPAT2 and USPATOLD enhanced with new
      custom IPC display formats
NEWS 5 MARPAT searching enhanced
NEWS 6 USGENE now provides USPTO sequence data within 3 days
      of publication
NEWS 7 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 MEDLINE and IMEDLINE reloaded with enhancements
NEWS 9 STN Express, Version 8.2 now available
NEWS 10 DCT now available as a replacement to DPCI
NEWS 11 IETREE reloaded with enhancements
NEWS 12 IMSPRODUCT reloaded with enhancements
NEWS 13 WDIINDEX/WDIINC/WDIIX enhanced with ECLA and current
      U.S. National Patent Classification
NEWS 14 IETCNR, IETIDAT and IFIUIDB enhanced with new custom
      IPC display formats
NEWS 15 CAS REGISTRY enhanced with additional experimental
      spectra
NEWS 16 CA/CANLUS and CASREACT patent number format for U.S.
      applications updated
NEWS 17 IPCI now available as a replacement to IIPCI
NEWS 18 EMRASE, EMRAI, and IEMRASE reloaded with enhancements
NEWS 19 STN AnaVist, Version 1, to be discontinued

NEWS EYDEFS REEDTADV 08 CURRENT WINDOWS VERSION IS V8.2
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

```

FILE 'HOME' ENTERED AT 02:08:42 ON 14 APR 2008
-> file medline biosis caplus
COST IN U.S. DOLLARS
SINCE FILE      TOTAL
ENTD.V.         SECTIONS
0.21            0.21
FULL ESTIMATED COST
FILE 'MEDLINE' ENTERED AT 02:09:15 ON 14 APR 2008
FILE 'BIOSIS' ENTERED AT 02:09:15 ON 14 APR 2008
Copyright (c) 2008 The Thomson Corporation
FILE 'CAPLUS' ENTERED AT 02:09:15 ON 14 APR 2008
THIS IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP.D ICSAGTERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
-> nutrition?
L1      1350660 NUTRITION?
-> tgf-b or tgf-beta
L2      90699 TGF-B OR TGF-BETA
-> 11 and 12
L3      514 L1 AND L2
-> 13 and (casein and whey)
L4      3 L3 AND (CASEIN AND WHEY)
-> 14 and 1970-2004/py
L5      2 L4 AND 1970-2004/PY
-> dup rem 15
PROCESSING COMPLETED FOR L5
L6      2 DUP REM L5 (0 DUPLICATES REMOVED)
=> d his
(FILE 'HOME' ENTERED AT 02:08:42 ON 14 APR 2008)
FILE 'MEDLINE BIOSIS CAPLUS' ENTERED AT 02:09:15 ON 14 APR 2008
I.1      1350660 NUTRITION?
I.2      90699 TGF-B OR TGF-BETA
I.3      514 I.1 AND I.2
I.4      3 I.3 AND (CASEIN AND WHEY)
I.5      2 I.4 AND 1970-2004/PY
L6      2 DUP REM L5 (0 DUPLICATES REMOVED)
-> d ti abs so l6 1-2
I.6      ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
TI      Method and ***casein*** / ***TGF*** - ***beta*** .2 composition
AR      for prophylaxis of type I diabetes especially in infants.
A      A ***nutritional*** common for the prophylaxis of insulin-dependent
diabetes mellitus type 1 in infants. The ***nutritional*** common
contains a protein source which includes ***casein*** rich in active
***TGF*** - ***beta*** 2 The ***casein*** rich in active
***TGF*** - ***beta*** 2 favors the induction of tolerance to oral
antigens in an infant susceptible to insulin-dependent diabetes mellitus
type 1
SO      DCT Int Appl., 14 pp.
CODEN: PIXXD2

```

ANSWER 2 OF 2 RIGHTS/CODVRIGHT (c) 2008 The Thomson Corporation on STN
 Food allergy, intolerance and prevention of atopic diseases
 About 2% of children in Europe suffer from cow's milk allergy, and 5%
 of the adult population suffer from food-induced clinical symptoms. Food
 allergy is often a disease of infancy and childhood. It can be simplified
 as a breakdown of oral tolerance or failure of its introduction. Mucosal
 antigen exposure generally leads to 2 important immunoregulatory processes
 which are not entirely understood. These are immune exclusion (immune
 elimination and immune regulation (oral tolerance) which can be defined
 as antigen-specific hypot or non-reactivity after prior mucosal
 (intestinal) exposure. The induction of oral tolerance is an active
 process which is finely tuned by the intestinal epithelium (including
 intraepithelial lymphocytes), specialized antigen-presenting cells and
 lymphocytes of the lamina propria. Different immunological processes are
 induced depending on the nature of the antigen, frequency and dose of
 administration, and the age of the individual. Administration of "low"
 antigen doses is associated with induction of suppressor cells which
 secrete regulatory cytokines such as ****TGF**** - ****heta**** and
 IL-4, IL-5, and others (Th2 type). However, antigen administration also
 leads to suppression of IgG, IgE, and cell-mediated immune responses
 which suggest a suppression of Th1- and Th2-dependent mechanisms. Anergy,
 clonal deletion, and other forms of immune deviation can be a part of the
 suppression of systemic immunity after mucosal antigen exposure. IgE and
 cell-mediated immune responses are implicated in a majority of clinical
 symptoms. The skin, the gastrointestinal tract, and the lungs are most
 commonly affected with clinical features ranging from mild to severe
 generalized (at times fatal) anaphylactic reactions. The incidence of
 milk allergy, and other food-induced symptoms in infancy have led to the
 design of ****nutritional**** prophylactic strategies with
 heat-denatured and enzyme-digested milk formulae on ****whev**** and
 ****casein**** basis with different degrees of hydrolysis. A number of
 prospective, randomized, and placebo-controlled clinical feeding studies
 seem to indicate a reduction in the incidence of milk allergies and of
 atopic eczema in infants of families with a positive atopic history
 (parent and/or sibling).
 Allergologie (****Nov 1997****) Vol. 20, No. 11, pp. 565-570. print.
 CODEN: ALLRDI. ISSN: 0344-5062.

-> eduardo?/au and schiffrin?/au
 L7 0 EDUARDO?/AU AND SCHIFFRIN?/AU
 -> denis?/au and breuille?/au
 L8 21 DENIS?/AU AND BREUILLE?/AU
 -> (denis breuille)/au
 L9 0 (DENIS BREUILLE)/AU
 -> stephanie?/au and blum-sperisen?/au
 L10 0 STEPHANIE?/AU AND BLUM-SPERISEN?/AU
 -> anne?/au and donnet-hughes?/au
 L11 0 ANNE?/AU AND DONNET-HUGHES?/AU
 -> magali?/au and faure?/au
 L12 0 MAGALI?/AU AND FAURE?/AU
 -> claudia?/au and roessle?/au
 L13 0 CLAUDIA?/AU AND ROESSLE?/AU
 => marco?/au and turini?/au

L14 0 MARCO?/AU AND TURINI?/AU

-> 16 and 18

L15 0 L6 AND L8

=> d his

(FILE 'HOME' ENTERED AT 02:08:42 ON 14 APR 2008)

FILE 'MEDLINE RISKS, CAPLUS' ENTERED AT 02:09:15 ON 14 APR 2008

T.1 1350660 NUTRITION? /AU
T.2 90699 TGF-R OR TGF-BETA
T.3 514 T.1 AND T.2
T.4 3 T.3 AND (CASEIN AND WHEY)
T.5 2 T.4 AND 1970-2004 /DV
T.6 2 DID REM T.5 (0 INDICATES REMOVED)
T.7 0 EDUARDO?/AU AND SCHIEPDM?/AU
T.8 21 DENIS?/AU AND REHILLLE?/AU
T.9 0 (DENIS REHILLLE?/AU
T.10 0 STEPHANIE?/AU AND BJIM-SPEISEN?/AU
T.11 0 ANNE?/AU AND DONNET-HUGHES?/AU
T.12 0 MAGALIE?/AU AND FAIRE?/AU
T.13 0 CLAUDIA?/AU AND ROESSE?/AU
T.14 0 MARCO?/AU AND TURINI?/AU
L15 0 L6 AND L8

-> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y) /N/HOLD.Y

COST IN U S DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 02:13:07 ON 14 APR 2008

SINCE FILE	TOTAL
ENTRY	SESSION
57.61	57.82
SINCE FILE	TOTAL
ENTRY	SESSION
-0.80	-0.80